Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis

This study was carried out to evaluate the vaccination effect of a virus-like particle (VLP) including the surface antigen 1 (SAG1) of Toxoplasma gondii as a potential vaccine for toxoplasmosis. The SAG1 virus-like particles (SAG1-VLPs) were expressed by Sf9 cells, and their expression was confirmed through cloning, RT-PCR analysis, and western blot method. The immunogenicity and vaccine efficacy of SAG1-VLPs were assessed by the antibody response, cytokine analysis, neutralization activity, splenocyte assay, and survival rates through a mouse model. In particular, IgG, IgG1, IgG2a, and IgA were markedly increased after immunization, and the survival rates of T. gondii were strongly inhibited by the immunized sera. Furthermore, the immunization of SAG1-VLPs effectively decreased the production of specific cytokines, such as IL-1β, IL-6, TNF-α, and IFN-γ, after parasite infection. In particular, the immunized group showed strong activity and viability compared with the non-immunized infection group, and their survival rate was 75%. These results demonstrate that SAG1-VLP not only has the immunogenicity to block T. gondii infection by effectively inducing the generation of specific antibodies against T. gondii, but is also an effective antigen delivery system for preventing toxoplasmosis. This study indicates that SAG1-VLP can be effectively utilized as a promising vaccine candidate for preventing or inhibiting T. gondii infection.

Download Full-text

Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis

Parasitology Research ◽

10.1007/s00436-010-1742-0 ◽

2010 ◽

Vol 106 (5) ◽

pp. 1079-1084 ◽

Cited By ~ 39

Author(s):

M. M. Liu ◽

Z. G. Yuan ◽

G. H. Peng ◽

D. H. Zhou ◽

X. H. He ◽

...

Keyword(s):

Toxoplasma Gondii ◽

Vaccine Candidate ◽

Potential Vaccine Candidate ◽

Potential Vaccine ◽

Microneme Protein

Download Full-text

Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice

Vaccine ◽

10.1016/j.vaccine.2009.08.043 ◽

2009 ◽

Vol 27 (47) ◽

pp. 6570-6574 ◽

Cited By ~ 47

Author(s):

Gao-Hui Peng ◽

Zi-Guo Yuan ◽

Dong-Hui Zhou ◽

Xian-Hui He ◽

Miao-Miao Liu ◽

...

Keyword(s):

Toxoplasma Gondii ◽

Vaccine Candidate ◽

Potential Vaccine Candidate ◽

Potential Vaccine ◽

Microneme Protein

Download Full-text

Toxoplasma gondii rhomboid protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis

Veterinary Parasitology ◽

10.1016/j.vetpar.2011.08.014 ◽

2012 ◽

Vol 184 (2-4) ◽

pp. 154-160 ◽

Cited By ~ 15

Author(s):

Jianhua Li ◽

Qianzhong Han ◽

Pengtao Gong ◽

Tuo Yang ◽

Baoyan Ren ◽

...

Keyword(s):

Toxoplasma Gondii ◽

Vaccine Candidate ◽

Potential Vaccine Candidate ◽

Potential Vaccine

Download Full-text

Improvement of the attenuated mutant strain of Brucella melitensis Rev1 as a potential vaccine candidate

Biologia ◽

10.1007/s11756-021-00695-z ◽

2021 ◽

Author(s):

Elham Mehdizadeh Marzenaki ◽

Ali Reza Saeedinia ◽

Mehdi Zeinoddini ◽

Ali Asghar Deldar

Keyword(s):

Mutant Strain ◽

Vaccine Candidate ◽

Brucella Melitensis ◽

Potential Vaccine Candidate ◽

Potential Vaccine

Download Full-text

Molecular identification and antigenic characterization of Babesia divergens Erythrocyte Binding Protein (BdEBP) as a potential vaccine candidate

Parasitology International ◽

10.1016/j.parint.2017.07.004 ◽

2017 ◽

Vol 66 (6) ◽

pp. 721-726 ◽

Cited By ~ 3

Author(s):

Shimaa Abd El-Salam El-Sayed ◽

Mohamed Abdo Rizk ◽

Mohamad Alaa Terkawi ◽

Naoaki Yokoyama ◽

Ikuo Igarashi

Keyword(s):

Molecular Identification ◽

Vaccine Candidate ◽

Binding Protein ◽

Potential Vaccine Candidate ◽

Antigenic Characterization ◽

Babesia Divergens ◽

Erythrocyte Binding ◽

Potential Vaccine

Download Full-text

Moraxella catarrhalis Bacterium without Endotoxin, a Potential Vaccine Candidate

Infection and Immunity ◽

10.1128/iai.73.11.7569-7577.2005 ◽

2005 ◽

Vol 73 (11) ◽

pp. 7569-7577 ◽

Cited By ~ 68

Author(s):

Daxin Peng ◽

Wenzhou Hong ◽

Biswa P. Choudhury ◽

Russell W. Carlson ◽

Xin-Xing Gu

Keyword(s):

Moraxella Catarrhalis ◽

Lipid A ◽

Vaccine Candidate ◽

Gene Encoding ◽

Potential Vaccine Candidate ◽

Whole Cells ◽

Potential Vaccine ◽

Major Surface ◽

Membrane Components ◽

Human Infections

ABSTRACT Lipooligosaccharide (LOS) is a major surface component of Moraxella catarrhalis and a possible virulence factor in the pathogenesis of human infections caused by this organism. The presence of LOS on the bacterium is an obstacle to the development of vaccines derived from whole cells or outer membrane components of the bacterium. An lpxA gene encoding UDP-N-acetylglucosamine acyltransferase responsible for the first step of lipid A biosynthesis was identified by the construction and characterization of an isogenic M. catarrhalis lpxA mutant in strain O35E. The resulting mutant was viable despite the complete loss of LOS. The mutant strain showed significantly decreased toxicity by the Limulus amebocyte lysate assay, reduced resistance to normal human serum, reduced adherence to human epithelial cells, and enhanced clearance in lungs and nasopharynx in a mouse aerosol challenge model. Importantly, the mutant elicited high levels of antibodies with bactericidal activity and provided protection against a challenge with the wild-type strain. These data suggest that the null LOS mutant is attenuated and may be a potential vaccine candidate against M. catarrhalis.

Download Full-text

Molecular Characterisation of the GdhA- Derivative of Pasteurella multocida B:2

Pertanika Journal of Tropical Agricultural Science ◽

10.47836/pjtas.44.1.10 ◽

2021 ◽

Vol 44 (1) ◽

Author(s):

Farahani Muhammad Azam ◽

Mohd. Zamri-Saad ◽

Raha Abdul Rahim ◽

Pramote Chumnanpuen ◽

Teerasak E-kobon ◽

...

Keyword(s):

Pasteurella Multocida ◽

Vaccine Candidate ◽

Animal Health ◽

Proteomic Profiling ◽

Robust Identification ◽

Sds Page ◽

Pcr Method ◽

Potential Vaccine ◽

Free Ranging ◽

World Organisation

Pasteurella multocida B:2 is an important veterinary pathogen causing fatal and acute haemorrhagic septicaemia (HS) in bovine. A live vaccine candidate, P. multocida B:2 GDH7 was reported to enable protection in cattle and buffaloes via intranasal (i. n.) administration. This potential vaccine was also reported to be self-transmitted from the vaccinated animal to the free-ranging animals allowing wider vaccination coverage. Prior to commercialisation, this potential vaccine requires further characterisation in accordance with the authoritative guidelines from the World Organisation for Animal Health (OIE). Hence, in this study, the potential vaccine strain, P. multocida B:2 GDH7 and the virulent parent strain were characterised through genomic and proteomic profiling. A crucial first step was to develop a sensitive yet simple and robust identification test to differentiate both strains which has been achieved by the development of a precise yet straightforward PCR method. In genomic profiling, Repetitive Extragenic Palindromic sequence-PCR (REP-PCR) was manipulated and both strains have a different display of genomic DNA band patterns. Some of the major OMPs were observed and prominent immunogens of P. multocida, OmpA and OmpH were observed to be expressed differently between these strains through SDS-PAGE analysis. In conclusion, a reproducible PCR detection method has enabled differentiation of both strains. Further characterisation of these strains shows a significantly different profile through genomic and proteomic profiling.

Download Full-text